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In neurological disorders, both acute and chronic neural stress can disrupt cellular proteostasis, resulting
in the generation of pathological protein. However in most cases, neurons adapt to these proteostatic
perturbations by activating a range of cellular protective and repair responses, thus maintaining cell
function. These interconnected adaptive mechanisms comprise a ‘proteostasis network’ and include the
unfolded protein response, the ubiquitin proteasome system and autophagy. Interestingly, several recent
studies have shown that these adaptive responses can be stimulated by preconditioning treatments,
which confer resistance to a subsequent toxic challenge – the phenomenon known as hormesis. In this
review we discuss the impact of adaptive stress responses stimulated in diverse human neuropathologies
including Parkinson's disease, Wolfram syndrome, brain ischemia, and brain cancer. Further, we examine
how these responses and the molecular pathways they recruit might be exploited for therapeutic gain.
This article is part of a Special Issue entitled SI:ER stress.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

Keywords:
ER stress
Proteasome
Parkinson's disease
Ischemia
Hormesis
Autophagy
Wolfram syndrome
Glioblastoma

Contents
1.
2.

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Stress adaptation in Parkinson's disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.1.
Endogenous adaptive response induced in PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2.2.
Adaptive responses induced by preconditioning in PD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3. Adaptation for Wolfram syndrome? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. Adaptation to ischemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.1.
Cellular responses to ischemia/reperfusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.2.
Ischemic tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.3.
UPR in ischemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.4.
UPR in ischemic tolerance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.5.
Autophagy in ischemic preconditioning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.6.
UPS in ischemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.7.
UPS in ischemic tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4.8.
tPA in ischemic tolerance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5. Adaptation in glioblastoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1. Introduction
The long-term health of cells critically relies on protein quality
control, since damaged, misfolded or aggregated proteins cause
proteotoxic stress that impairs cell function (Glickman and Ciechanover, 2002; Morimoto, 2008; Goldberg, 2003; Ihara et al.,
2012). The healthy brain adapts to cellular stresses that disrupt
protein homeostasis (referred to as proteostasis) (Balch et al.,
2008). Proteostatic perturbations are induced by a variety of
stressors including (but not limited to) pathological protein inhibition of protein clearance pathways and oxygen deprivation.
Depending on the type and intensity of the stress, distinct but
interconnected adaptive responses are set in motion; these include
autophagy, the unfolded protein response (UPR) (Box 1), the ubiquitin proteasome system (UPS) (Box 2), the anti-oxidant response,
and heat- and cold-shock responses (Martins et al., 2011; Mollereau et al., 2014; Mollereau, 2015). A subtoxic level of stress engages these adaptive responses and elicits preconditioning, thus
conferring protection against further toxic insults (Mattson, 2008;
Rzechorzek et al., 2015). This phenomenon, generally referred to as
‘hormesis’, is strongly conserved in evolution and can be induced
by many and varied perturbations including (among others) oxidative stress, ER stress, inﬂammatory stimuli, and temperature
shift, all of which disrupt cellular proteostasis (Rutkowski et al.,
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2006; Calabrese, 2014; Mollereau et al., 2014; Rzechorzek et al.,
2015). Of note, a recent review compiled the effect of 154 distinct
conditioning agents used in preconditioning or postconditioning
experiments (Calabrese, 2016a). In the last few years an increasing
number of studies have focused on the importance of hormesis in
pathologies such as neurodegenerative disease, cancer, diabetes
and aging (Hetz and Mollereau, 2014; Martins et al., 2011; Mollereau, 2013; Mollereau et al., 2014; Perri et al., 2015). In this review, we focus on Parkinson's disease (PD), Wolfram syndrome,
brain ischemia, and brain cancer (glioma) for which perturbations
of cellular proteostasis (and in some cases adaptations to these)
have been clearly established. We also discuss the therapeutic
potential of engaging or interfering with hormetic responses in a
context-dependent manner.

2. Stress adaptation in Parkinson's disease
PD is a movement disorder characterized by the selective loss
of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc) resulting in motor symptoms such as bradykinesia,
rigidity and resting tremor (Hirsch et al., 2013). DA neuron loss
involves severe proteostatic alterations, evidenced by the accumulation of Lewy bodies - cytoplasmic protein inclusions enriched
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in α-synuclein. A subset of patients with early-onset familial PD
carry mutations or duplications in the gene coding for α-synuclein,
which have been linked to misfolding and aggregation of the
protein (Conway et al., 1998). Proteostatic perturbation, misfolding
and subsequent aggregation of α-synuclein are believed to play
major roles in the pathomechanism of PD, which belongs to a family of neurological conditions known as protein misfolding disorders (PMD) (Hetz and Mollereau, 2014; Soto, 2003). Here we
highlight the tight association between genes that are frequently
mutated in familial PD and alterations in the UPR machinery. We
will also discuss the potential value of modulating ER-hormesis as
a neuroprotective mechanism in PD.
2.1. Endogenous adaptive response induced in PD
The UPR is an adaptive response that is activated to cope with
ER stress (Box 1). In PD, ER stress components constitute early
biomarkers; for example phosphorylated PERK is found in DA
neurons of the SNpc and colocalizes with α-synuclein (Hoozemans
et al., 2007; Hoozemans et al., 2012). Induction of most UPR signaling responses is reported in different toxicological models of PD
in vitro and in vivo (Bauereis et al., 2011; Mercado et al., 2013). In
addition, the generation of neurons from induced pluripotent stem
cell (iPSC) lines derived from PD patients carrying α-synuclein
mutations revealed a major dysfunction in proteostasis (Chung
et al., 2013). This study showed that ER stress and UPR activation
are prominent features in PD-associated cell alterations. Several
studies also report that an impairment in vesicular trafﬁcking is
commonly observed in PD, which may be responsible for UPR
activation and perturbation of proteostasis (Cooper et al., 2006;
Gitler et al., 2008) and is reviewed in (Mercado et al., 2015).
In the last few years it has become clear that the UPR is a
double-edged sword in PD: it is cytoprotective when activated at
moderate levels during the early course of the disease, but cytotoxic when activated in an intense and sustained manner in the
late phase of the disease (Hetz and Mollereau, 2014; Silva et al.,
2005). Here we outline the adaptive arms of the UPR that involve
several protective pathways, allowing neurons to cope for many
years with cellular stress in PD (Fig. 1).
Several studies have described an important contribution of the
α subtype of ATF6 (ATF6α) to neuroprotection in mouse models of
PD. Mice injected intraperitoneally with the DA neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) - which induces oxidative stress, ubiquitin inclusions and a selective loss of
DA neurons - exhibited an activation of ATF6α and ERAD in DA
neurons. Importantly, mice deﬁcient for ATF6α were more sensitive to MPTP compared to wild type animals indicating that ATF6α
confers neuroprotection (Egawa et al., 2011). Interestingly, another
study proposed that neuroprotection is mediated at least in part
by ATF6α in the astrocytes of mice submitted to MPTP treatment
suggesting that UPR-associated neuroprotection may proceed
through non-cell autonomous mechanisms (Hashida et al., 2012).
The authors showed that MPTP induces activation of ATF6α in
astrocytes, which in turn triggers the production of brain-derived
neurotrophic factor (BDNF) and anti-oxidative genes, such as heme
oxygenase-1 (HO-1) and the cystine/glutamate antiporter (xCT),
conferring protection against DA neuron loss. Other essential
neurotrophic factors including cerebral dopamine neurotrophic
factor (CDNF) and mesencephalic astrocyte-derived neurotrophic
factor (MANF) confer protection to DA neurons whilst interacting
with UPR function (Voutilainen et al., 2015). Together these studies
indicate that ATF6α is an important player in the adaptive response of DA neurons. A recent study showed that the ATF6α
protective arm is inhibited by α-synuclein during the course of the
disease (Credle et al., 2015). Speciﬁcally, α-synuclein interacted
with ATF6α and inhibited the ER-Golgi transit of COPII vesicles that

605

is required for ATF6α activation. This resulted in impaired ATF6α
activation, reduced ERAD activity and increased apoptosis of DA
neurons. The dysfunction of the ERAD machinery leads to the accumulation of ERAD substrates which is commonly observed in
several neurodegenerative diseases including Alzheimer’s disease
(AD), amyotrophic lateral sclerosis (ALS) and PD (Abisambra et al.,
2013; Chung et al., 2013; Nishitoh et al., 2008). Thus although αsynuclein can primarily induce ER stress (Gorbatyuk et al., 2012),
its speciﬁc interaction with ATF6α leads to the impairment of UPR
adaptive function and ultimately contributes to disease pathogenesis, possibly by exacerbating protein misfolding.
The PERK/eIF2α/ATF4 branch, which is associated with activation of the transcription factor CHOP (a potentially toxic output of
the UPR) also contributes to neuroprotection in PD (Bouman et al.,
2011; Sun et al., 2013). For example, pharmacological enhancement of eIF2α phosphorylation with salubrinal has neuroprotective effects in PD models in vivo (Colla et al., 2012). It was also
shown that Parkin, mutated in an autosomal recessive form of
early-onset PD, is induced by ATF4 upon mitochondrial or ER
stress to promote neuroprotection (Bouman et al., 2011). The loss
of ATF4 in neuronal PC12 cells treated with MPTP or 6-hydroxydopamine (6-OHDA) resulted in decreased Parkin expression
and enhanced death (Sun et al., 2013). Notably Parkin, which is
also induced by the mitochondrial UPR, eliminates damaged mitochondria by activating mitophagy (Jin and Youle, 2013; Narendra
et al., 2008). Interestingly, it was proposed that Parkin-mediated
cell protection does not require its ubiquitin-ligase activity suggesting that it acts independently of the proteasome (Bouman
et al., 2011).
Activation of IRE1/XBP1 also induces an efﬁcient adaptive response in PD; it leads to the expression of chaperones such as BiP/
GRP78 and ERAD factors that contribute to neuroprotection. We
have reported that the developmental ablation of XBP1 in the
nervous system protects DA neurons against a PD-inducing neurotoxin through an ER-hormesis compensatory mechanism
(Valdes et al., 2014). Neuronal survival was mediated in part by
preconditioning that resulted from the induction of an adaptive ER
stress response. Furthermore, the consequences of manipulating
the UPR network in PD has been tested using gene therapy (Castillo et al., 2015). We recently employed gene therapy to deliver
active XBP1s into the SNpc, a strategy that provided neuroprotection and reduced striatal denervation in PD models (Valdes
et al., 2014). Similarly, in mice treated with MPTP, adenoviral expression of XBP1s prompted survival of DA neurons. Neuroprotection was also observed by overexpression of BiP/GRP78 in rats
expressing human α-synuclein (Gorbatyuk et al., 2012). BiP/GRP78
expression resulted in the downregulation of PERK and CHOP.
Furthermore, in a study performed in C. elegans and human neuroblastoma cells, it was shown that BiP/GRP78 expression depends
on the leucine-rich repeat kinase 2 (LRRK2), the most commonly
mutated protein in PD. Induction of BiP/GRP78 resulted in neuroprotection against 6-OHDA treatment or α-synuclein expression
possibly through activation of the p38 pathway (Yuan et al., 2011).
Moreover, a mutated form of LRRK2 (G2019S) resulted in chronic
activation of p38 in murine neurons and age-related DA-speciﬁc
neurodegeneration in nematodes. Together these studies highlight
the strong link between LRRK2 and the UPR, as well as the important roles of IRE1/XPB1 and Bip/GRP78 in the adaptive response in PD.
2.2. Adaptive responses induced by preconditioning in PD
In the last few years, Drosophila has become an important
model to study the contribution of ER stress and mitochondrial
dysfunction to cell death and neurodegeneration (Coulom and
Birman, 2004; Mollereau, 2009; Rasheva and Domingos, 2009;
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Fig. 1. The adaptive UPR in Parkinson's disease. In PD the UPR is activated. MPTP or 6-OHDA treatments induce ATF6 activation, oxidative stress and ubiquitin inclusions,
which inhibit the proteasome. ATF6 confers neuroprotection to DA neurons by promoting ERAD factors that target misfolded protein to the proteasome and XBP1, which
further alleviates ER stress by inducing expression of chaperones. ATF6 also induces the expression of BDNF, HO-1 and xCT that protects DA neurons. ATF6-mediated
protection is hampered by α-synuclein which interacts with ATF6, inhibiting its activation by interfering with trafﬁcking of COPII vesicles. The PERK/ATF4 branch is also
activated and contributes to neuroprotection by inducing the expression of Parkin which in turn promotes mitophagy. α-synuclein also associates with PERK and may
interfere with its function. IRE1/XBP1 contributes to neuroprotection by inducing BiP expression which limits overactivation of PERK and proapoptotic CHOP expression. BiP
can also be induced via LRRK2 and the p38 pathway.

Ryoo and Steller, 2007; Ryoo, 2015). Taking advantage of the
crystal-like array that is formed by the 800 ommatidia of the adult
Drosophila eye, which allows a ﬁne visualization of degeneration,
homologs of the UPR have been characterized in models of retinitis pigmentosa and PD (Kang and Ryoo, 2009; Lessing and
Bonini, 2009; Mollereau and Domingos, 2005; Ryoo et al., 2007).
In several studies, pharmacological or genetic manipulation of the
UPR prompted preconditioning, whereby the adaptive arms of the
UPR were activated offering protection from neurodegeneration in
models of PD (Mollereau et al., 2014; Tsujii et al., 2015). The idea
that ER-preconditioning/ER-hormesis may protect against neurodegeneration followed from the observation that Drosophila mutant in the ER-resident chaperone NinaA exhibited UPR activation
and resistance to various apoptotic stimuli (Mendes et al., 2009).
This result prompted the analysis of preconditioning of the ER in
several animal and cellular models of PD. Preconditioning of the
ER induced via injection of the ER stressor tunicamycin (inhibitor
of N-glycosylation) reduced DA neuron loss and improved locomotor activity after stereotaxic injection of 6-OHDA in mice. Similar protection by tunicamycin administration was observed in a
human neuroblastoma cell line treated with 6-OHDA and in Drosophila expressing human α-synuclein (Fouillet et al., 2012). Interestingly, UPR-mediated protection required XBP-1 and was associated with an increase in protective autophagy. This indicates
an important protective role of the IRE1/XBP1 pathway and autophagy in preconditioning of the ER in models of PD.
As mentioned, speciﬁc ablation of XBP1 in the nervous system
has been associated with an adaptive ER stress response in models
of PD but also in models of ALS and HD (Hetz et al., 2009; Matus
et al., 2009; Valdes et al., 2014 ; Vidal et al., 2012). In the ALS
model, XBP1 ablation resulted in upregulated autophagy that
protected mutant SOD1 transgenic mice against disease by eliminating mutant SOD1 aggregates (Hetz et al., 2009). Virtually
identical observations were observed in HD models (Vidal et al.,
2012). The neuroprotective effects of targeting XBP1 in the SNpc

were correlated with the upregulation of several ER chaperones
and autophagy markers (Valdes et al., 2014). Together these results
indicate that XBP1 is an important switch in the control of the ER
adaptive response.
ER-preconditioning also induces an anti-oxidant response that
contributes to neuroprotection (Hara et al., 2011; Mendes et al.,
2009). It was observed that pretreatment with thapsigargin (an
inhibitor of the sarcoplasmic/ER Mg2 þ /Ca2 þ ATPase; SERCA)
conferred resistance in SH-SY5Y neuroblastoma cells challenged
with 6-OHDA by upregulating HO-1. Thapsigargin stimulated the
anti-oxidant response element (ARE) upstream of HO-1 (Hara
et al., 2011). Interestingly, inhibition of store-operated calcium
entry (SOCE) has also been shown to be protective against MPTP in
PC12 cells. The pharmacological inhibition of SOCE, which resulted
in inhibition of the release of intracellular Ca2 þ from the ER, led to
the expression of Homer1a, a scaffold protein with an anti-oxidant
potential (Li et al., 2013).
A requirement for future therapy will be to promote a long
lasting ER-adaptive response by ﬁne-tuning the intensity of ER
stress to achieve the best protection, whilst suppressing possible
adverse effects due to toxic UPR activation. Several neuroprotective compounds and treatments function by inhibiting activation
of the PERK-eIF2α-CHOP pathway in models of PD. For instance,
administration of candesartan cilexetil, a selective and high-afﬁnity Angiotensin II receptor antagonist, reduced ER stress toxicity
induced by rotenone in a rat model of PD as evidenced by inhibition of ATF4, CHOP, and p53 upregulated modulator of apoptosis (PUMA) (Wu et al., 2013). Another potential therapeutic
strategy is the induction of ER hormesis by hypothermia, which
has been shown to protect human cortical neurons by priming
proteostatic pathways including adaptive outputs of the UPR
(Mollereau, 2015; Rzechorzek et al., 2015). Adaptive UPR responses
in human neurons were required for hypothermic protection
against both oxidative and ER stress – important contributors to
acute and chronic neuronal injury (Rzechorzek et al., 2015).
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Box 1–the unfolded protein response
The UPR is an adaptive cellular response that aims to
safeguard proteostasis in the face of misfolded protein
accumulation within the endoplasmic reticulum (ER) (Walter
and Ron, 2011; Wang and Kaufman, 2016). Under basal
conditions, the UPR chaperone binding immunoglobulin
protein (BiP/GRP78) associates with (and thereby inhibits)
the three main ER resident transmembrane stress tranducers:
protein kinase RNA-like ER kinase (PERK), inositol-requiring
enzyme 1 (IRE1), and activating transcription factor 6 (ATF6).
When ER stress is detected, BiP/GRP78 associates with
misfolded protein, thus releasing these three ER stress signal
transducers, which in turn activate a tripartite signaling
cascade to restore proteostasis. Downstream UPR outputs
include attenuation of protein synthesis, increased expression of chaperones that assist with protein folding, and
degradation of misfolded proteins via ER-associated protein
degradation (ERAD) (Hetz et al., 2015). UPR activation also
increases proteasomal activity and macroautophagy (hereinafter referred to as autophagy) (Klionsky et al., 2016).
Activated PERK phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (eIF2), resulting in the rapid
and transient attenuation of protein translation and the
reduced import of newly synthesized proteins into the ER.
Despite the downregulated translation of most transcripts,
translation of activating transcription factor 4 (ATF4) mRNA is
induced; this transcription factor then facilitates the expression of ER resident chaperones as well as proteins involved in
autophagy, anti-oxidant responses, amino acid metabolism
and (in the case of insurmountable ER stress) C/EBPhomologous protein (CHOP) which induces apoptosis (Walter and Ron, 2011). ATF4 and CHOP can also form heterodimers that activate genes encoding ER adaptive functions as
well as increasing the translational machinery to restore
protein synthesis (Han et al., 2013). The second and most
conserved proximal UPR transducer, IRE1, carries both Ser/
Thr kinase and endoribonuclease activities within its cytoplasmic domain. Upon dimerization and autophosphorylation, IRE1 endoribonuclease initiates the unconventional
splicing of x-box binding protein 1 (XBP1) mRNA, producing
the transcription factor XBP1s (spliced XBP1). XBP1s in turn
induces the expression of genes encoding proteins involved
in co-translational translocation, lipid synthesis, inflammation and other processes, as well as signal recognition
particle receptor, ER chaperones, and ERAD proteins (Hetz
et al., 2011; Sidhu et al., 2015). IRE1 endoribonuclease also
degrades specific mRNAs associated with the ER, through a
mechanism known as regulated IRE1-dependent decay
(RIDD) (Coelho and Domingos, 2014; Maurel et al., 2014).
Finally, IRE1 also activates the Jun amino terminal kinase
(JNK) stress pathway and the apoptosis signal regulating
kinase 1 (ASK1) (Urano et al., 2000). The third UPR
transducer, ATF6, translocates to the Golgi where it is cleaved
by site 1 and site 2 proteases (S1P and S2P). The released
cytosolic ATF6f is a transcription factor, which induces the
expression of XBP1 and ERAD proteins (Walter and Ron,
2011). ATF6 is the major transcription factor that activates
genes encoding the adaptive UPR (Wu et al., 2007). Considering the major role of the UPR in proteostasis, it is intuitive
that deregulation of these processes are pathogenic (Wang
and Kaufman, 2012)
However, in contrast to previous work in prion-diseased mice
(Moreno et al., 2012), Rzechorzek et al. showed that PERK was an
important contributor to neuroprotective adaptation of the UPR
and proposed that cold-shock proteins would interact with this
pathway – a hypothesis recently supported for cold-inducible RNA
binding motif-3 (RBM3) in vitro (Zhu et al., 2015).
Further evidence that UPR manipulation represents a
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promising therapeutic strategy speciﬁcally in PD unexpectedly
came from tobacco users. Indeed, multiple epidemiological studies
have shown that smokers are less prone to develop PD than nonsmokers (Ritz et al., 2007). One proposed mechanism is that
chronic mild activation of nicotinic receptors confers neuroprotection. Nicotine has been shown to be protective in several
models of PD (Quik et al., 2015). This could arise from the upregulation of neuronal nicotinic acetylcholine receptors (nAChRs)
that occurs via nicotine-mediated pharmacological receptor chaperoning within the ER (Henderson and Lester, 2015). A recent
study found that the protection mediated by nicotine is due to the
attenuation of the UPR in DA neurons (Srinivasan et al., 2016).
Overall, the ﬁndings of many recent studies modeling PD as well as
other neurodegenerative diseases reﬂect the complex nature of
ﬁne-tuning proteostatic mechanisms, suggesting that cell type and
disease stage may signiﬁcantly inﬂuence the outcome.

3. Adaptation for Wolfram syndrome?
Wolfram syndrome is one of the best examples that highlights
the existence of a tight UPR control to avoid its dysregulation, loss
of proteostasis and pathology. Wolfram syndrome is characterized
not only by endocrine manifestations such as early-onset diabetes
mellitus and diabetes insipidus, but also by neurological dysfunction including progressive optic nerve atrophy, ataxia beginning in early adulthood, brain stem atrophy, and psychiatric
manifestations (Barrett et al., 1995; Fonseca et al., 2009; Mollereau
et al., 2014; Urano, 2016). Wolfram syndrome is caused by mutations in the WFS1 gene encoding an ER-resident membrane glycoprotein which regulates cellular calcium homeostasis (Inoue
et al., 1998; Lu et al., 2014). First described in pancreatic β cells and
neurons, WFS1 attenuates the UPR by speciﬁcally targeting ATF6α
for degradation by the proteasome and stabilizing HRD1 (Fonseca
et al., 2010). In the visual system, loss of WFSI function induces an
exacerbated ER stress leading to optic nerve atrophy and impairment of visual function (Bonnet Wersinger et al., 2014; Inoue et al.,
1998). Thus WFS1 is a critical regulator of the UPR, which limits its
hyperactivation and neuronal cell death. In Wolfram syndrome,
UPR adaptation is likely to proceed in a limited fashion because
these patients develop neurodegeneration over a protracted period. It was previously shown that IRE1 inhibits ER membrane
permeabilization mediated by Bax and Bak (and thus apoptosis) in
cells undergoing ER stress (Kanekura et al., 2015). Inhibition of
IRE1 signaling led to the accumulation of the BH3 domain-containing protein Bnip3, which in turn triggers the oligomerization
of Bax and Bak in the ER membrane and ER membrane permeabilization. Consequently, in response to ER stress, cells lacking IRE1
are susceptible to the leakage of ER contents, which is associated
with the accumulation of calcium in mitochondria, oxidative stress
in the cytosol, and ultimately cell death. Thus increasing proteasomal ﬂux, counteracting ER membrane permeabilization by IRE1
or priming other UPR branches to resist the downstream effects of
wsf1 mutation may prove to be valuable therapeutic approaches
for Wolfram syndrome.

4. Adaptation to ischemia
4.1. Cellular responses to ischemia/reperfusion
Brain ischemia is a major cause of adult mortality and disability
and manifests by a reduction of blood ﬂow to the brain, resulting
in a lack of cellular oxygen, glucose, and energy, altered cellular
homeostasis and ultimately cell death (Doyle et al., 2008; Hofmeijer and van Putten, 2012). Global ischemia affects the entire

608

B. Mollereau et al. / Brain Research 1648 (2016) 603–616

Fig. 2. The adaptive UPR in brain ischemia. In brain ischemia, excitotoxicity is induced by an excess of glutamate which overactivates NMDA receptors. This leads to rapid
inﬂux of Ca2 þ into the cytoplasm. The increase of intracellular Ca2 þ has several deleterious consequences including the activation of calpains that cleave many substrates
leading to proteostatic disturbance, the loss of calcium homeostasis in the mitochondria followed by oxidative stress and ATP depletion, and inhibition of the SERCA pump at
the ER with subsequent UPR activation. Ischemic preconditioning induces a wide range of protective responses favoring UPR adaptive arms (BiP, HERP), autophagy, the
antioxidant response (SOD1, catalase) and proteasomal activity. Postconditioning also increases proteasome activity, which degrades Bim and increases Bcl-2 hence reducing
apoptosis. These treatments awaken cellular adaptive mechanisms which, together with HIF1 responses, allow the cell to better resist stress and favor a fast return to normal
proteostasis after injury. Moderate stimulation of the UPR activates its adaptive pathways, which is essential to restore protein homeostasis. PERK phosphorylates eIF2α and
inhibits translation which is at ﬁrst beneﬁcial because it reduces the load of misfolded proteins. GCN2 also phosphorylates eIF2α and induces an adaptive program that is
independent of this phosphorylation event. The dephosporylation of eIF2α by GADD34 restores protein synthesis. This is favored by eIF2β (induced by TLR activation) and
allows expression of survival proteins and progressive resumption of proteostasis. IRE1 is a key adaptive response factor in ischemia; its speciﬁc modulation by interacting
with Hsp72 or BI-1 promotes XBP1-dependent and independent responses to ensure cell survival while inhibiting JNK mediated cell death. Tg: thapsigargin.

brain after cardiac arrest, whereas focal ischemia follows an ischemic stroke after vessel occlusion. An important event during
brain ischemia is the excitotoxicity that ensues due to the release
of glutamate, its extracellular accumulation and the subsequent
post-synaptic toxic activation of glutamate receptors (Fig. 2, Rossi
et al., 2000). This triggers a massive increase in intracellular calcium, leading to the activation of calpains (Ca2 þ -dependent proteases), which in turn cleave many cellular substrates such as
proteins of the cytosolic compartment, plasma membrane, synaptic vesicles and mitochondria (Bevers and Neumar, 2008). To
date, there are two main therapies to enable reperfusion: thrombolysis by tissue-type plasminogen activator (tPA) (NINDS, 1995)
and more recently mechanical removal of the clot by thrombectomy (Ding, 2015). Due to technical limitations, thrombolysis by tPA
remains the gold standard treatment, aiming to dissolve the blood
clot and restore cerebral blood ﬂow to ischemic tissues. However,
the therapeutic window of thrombolysis is restricted to the ﬁrst
few hours after stroke onset and possible deleterious effects due to
reperfusion (termed ischemia reperfusion injury, IRI) have to be
considered. Despite a clear beneﬁcial effect overall, in certain
conditions tPA can trigger neurotoxicity (Lemarchant et al., 2012)
and reperfusion induces a massive burst of reactive oxygen species
and calcium overload (Bull et al., 2008; Parsons et al., 1999). The
hypoxia-inducible transcription factors (HIF-1α, -2α, -3α) are essential actors in the cellular response to hypoxia. Low oxygen levels are detected by the oxygen sensors prolyl-hydroxylases (PHD),
which become inactive. This in turn relieves the inhibition of PHD
on HIF1α, allowing its dimerization with HIF1β and the expression
of multiple genes involved in the protective response against
oxygen deprivation (Semenza, 2007).

4.2. Ischemic tolerance
The phenomenon of ischemic preconditioning was ﬁrst established in the heart, but studies from the last two decades have
provided compelling evidence that it also exists in the brain (N
et al., 2015; Stetler et al., 2014). Robust evidence of neuronal ischemic preconditioning has been developed in cellular, tissue
culture and animal models, i.e. sublethal ischemic insults conferring protection against subsequent toxic ischemic insults has
helped to elucidate mechanistic elements of these adaptive responses (Caldeira et al., 2014; Rybnikova and Samoilov, 2015).
Using hippocampal and olfactory cortical slices, it has been demonstrated that a single short anoxia or rapid cycle of anoxia increases the resistance to severe anoxia, preventing calcium overload (Perez-Pinzon et al., 1999). Another technique of hypoxic
preconditioning is exposure to mild hypobaric hypoxia that
naturally occurs at moderate high altitude or experimentally in a
hypobaric chamber. It induces reprogramming of cardio-pulmonary and metabolic processes, including erythropoiesis, vascular
remodeling, pulmonary changes and cardiac hypertrophy (Rybnikova and Samoilov, 2015). The protection that is activated by hypoxic preconditioning involves several neuroprotective pathways
that contribute to the adaptive response. For example, mild stimulation of NMDA receptors is known to induce adaptation rather
than excitoxicity and has been reviewed elsewhere (Caldeira et al.,
2014; Hardingham and Bading, 2010; Shpargel et al., 2008; Watters and O'Connor, 2011). Neuroprotection also relies on cellular
processes implicated in proteostasis such as the UPR, the UPS or
autophagy, but also the expression of neuroprotective factors such
as HIF1 and tPA.
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4.3. UPR in ischemia
During stroke, the loss of calcium homeostasis triggers ER
stress and the UPR. Functionally, ischemia inhibits SERCA - the
pump that is essential for the uptake of Ca2 þ into the ER (Fig. 2,
Parsons et al., 1997). Subsequently, the loss of calcium homeostasis
induces ER stress (Lehotsky et al., 2009; Paschen, 2003). Activation
of the UPR has been observed in several rodent models of ischemic
stroke (DeGracia and Montie, 2004; Nakka et al., 2010; Su and Li,
2015). In these models, it was shown that inhibition of protein
synthesis requires PERK-dependent phosphorylation and inhibition of eIF2α. Hypoxia also stabilizes the UPR transcription factor
ATF4 to promote an adaptive response (Scortegagna et al., 2014).
Furthermore, IRE1 is activated during stroke, which leads to the
expression of chaperones and ERAD proteins. ATF6 is more difﬁcult to detect but was activated after middle cerebral artery occlusion (MCAO) in rats (Rissanen et al., 2006). Although protein
synthesis is strongly inhibited during ischemia, a few proteins
including CHOP are upregulated. CHOP was detected in several
rodent models of ischemia including those involving bilateral
common carotid artery occlusion, which induces global brain
ischemia (Tajiri et al., 2004). Similar results were obtained in other
models of brain ischemia (Nakka et al., 2010; Osada et al., 2010;
Paschen et al., 1998; Paschen et al., 2003 ; Roberts et al., 2007).
CHOP induces the expression of apoptotic genes and the translational apparatus leading to increased protein synthesis, ER protein
misfolding, oxidative stress and cell death (Han et al., 2013).
Moreover, mice deﬁcient in CHOP are protected from the injury
induced by bilateral common carotid artery occlusion, indicating
that CHOP is a key apoptotic player during the ischemic insult
(Tajiri et al., 2004).
The current dogma therefore is that the PERK branch of the
UPR is protective under modest UPR activation but contributes to
cell death during severe acute stress (Rutkowski et al., 2006;
Walter and Ron, 2011). This dual function of PERK is reﬂected at
the level of eIF2α phosphorylation, controlled by the phosphatase
GADD34 (growth arrest and DNA damage–inducible 34), the regulatory subunit of protein phosphatase 1 which helps to resolve
the UPR (and mRNA translation) once proteostasis is re-established. Selective inhibition of this pathway via CHOP deletion (and
thus reduced GADD34 activation) can protect from ER stress by
inducing a prolonged phosphorylation of eIF2α (Marciniak et al.,
2004; Harding et al., 2009). However, prolonged phosphorylation
of eIF2α can also lead to cell death, in particular in secretory cells
as observed in pancreatic beta cells treated with salubrinal, a selective inhibitor of eIF2α phosphatases (Boyce et al., 2005; Cnop
et al., 2007). It is thus clear (and intuitive) that prolonged inhibition of protein synthesis can lead to cell death (Cnop et al., 2007)
and overcoming this translational repression may prove to be an
important therapeutic target, as proposed for neurodegeneration
(Moreno et al., 2012). Interestingly, it has been suggested that Tolllike receptors (TLRs) inhibit phosphorylation of eIF2α and CHOP
expression by activating eIF2β, a guanine nucleotide exchange
factor (GEF). This maintains a long lasting physiological ER stress,
enabling the synthesis of essential proteins in macrophages whilst
beneﬁting from the protective arms of the UPR (Woo et al., 2012).
4.4. UPR in ischemic tolerance
Despite several lines of evidence that ER stress and UPR activation promote cell death in ischemia models, other studies have
shown that the UPR is also activated by transient preconditioning
treatments and contributes to neuroprotection. One study examined the temporal expression of chaperones and folding proteins in rats submitted to transient global ischemia, using the
2-vessel occlusion model. The authors found that while heat shock
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protein 70 (Hsp70) is ﬁrst expressed in the cytoplasm (within
30 min), this is followed by the induction of Hsp60 in the mitochondria, and then HERP, GRP78, GRP94, calnexin and PDI in the
ER lumen at a later stage (4–24 h) (Truettner et al., 2009). Another
study in C. elegans showed that the UPR is required for resistance
to hypoxia in animals carrying a mutation in the rrt-1 gene, encoding an arginyl-transfer RNA (tRNA) synthetase. This enzyme is
essential for protein translation and the level of hypoxia resistance
in C. elegans was inversely correlated to the translation rate (Anderson et al., 2009). In a follow-up study, the same group found
that resistance to hypoxia required IRE-1 but not XBP-1 or ATF6. In
addition GCN2, a kinase known to phosphorylate eIF2α upon
amino acid deﬁciency, induces an adaptive transcriptional response required for adaptation to hypoxia (Mao and Crowder,
2010). Interestingly the phosphorylation of eIF2α by GCN2 was not
required for this adaptation, suggesting that this mechanism is
independent of translational suppression. In another C. elegans
study, it was proposed that the Heterochromatin Protein 1 (HP1)
homolog HPL-2 plays an important role in the induction of UPR
during preconditioning (Kozlowski et al., 2014). Loss of HPL-2 in
animals led to a protective response dependent on XBP1. Although
resistance of these animals to hypoxia was not tested in this study,
these results suggest that chromatin structure may be modulated
by stress to induce UPR-mediated protection, either through direct
transcriptional effects or through more global changes in chromatin organization.
The protective pathways activated by preconditioning downstream of the UPR are yet to be fully elucidated. One possibility is
that the adaptive response curtails the ER stress-induced cell
death that might otherwise occur in response to ischemic injury.
This idea was recently supported by a study exploiting the brain
protection mediated by postconditioning i.e. a conditioning
treatment applied shortly after injury (Liu et al., 2014). The authors
found that postconditioning of rats previously subjected to
ischemia/reperfusion increased the protein levels of chaperone
BiP/GRP78 and the anti-apoptotic factor Bcl-2 but decreased
phosphorylated-eIF2α, and the expression of pro-apoptotic CHOP,
caspase-12, Bcl-2-interacting mediator of cell death (Bim) and
cleaved-caspase-3 (Liu et al., 2014). The molecular switch that
favors pro-survival in ischemia is still unknown. A potential candidate for regulating this switch is Hsp72, which has been shown
to reduce tissue injury in experimental models of stroke and
myocardial ischemia (Morimoto et al., 1997). Indeed, it was proposed that Hsp72, which is induced by ER stress, enhances survival
by interacting with and activating IRE1 endoribonuclease activity.
This results in XBP1 splicing, activation of its target genes and the
attenuation of apoptosis in ER stress conditions (Gupta et al.,
2010). Another possible candidate to regulate the switch toward
cell death or survival is Bax-inhibitor-1 (BI-1) (Chae et al., 2003,
2004). In models of hepatic and liver ischemia-reperfusion, BI-1
was shown to protect cells from extensive ER stress (Bailly-Maitre
et al., 2006). In contrast to Hsp72, which increases IRE1 activity,
BI-1 limits IRE1 endoribonuclease activity (Lisbona et al., 2009).
Thus BI-1 may protect cells by suppressing IRE1 signaling. Interestingly the lack of BI-1 also resulted in neuroprotection under
nutrient deprivation. In BI-1 deﬁcient cells, an increased IRE1 led
to JNK activation and autophagy (Castillo et al., 2011). BI-1 is also
an important regulator of neuronal survival in vivo during ischemia-reperfusion (Krajewska et al., 2011). BI-1-deﬁcient mice display increased sensitivity to cerebral ischemia-reperfusion injury
by MCAO. Reversibly, enforced neuronal expression of BI-1 confers
protection from IRI in brain. Reduced phosphorylation of the JNK
substrate c-JUN was observed in brain tissue after MCAO, consistent with the notion that BI-1 affords neuroprotection by suppressing IRE1 signaling (Krajewska et al., 2011). Thus BI-1 can favor death or survival upon ER stress activation and further work is
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needed to understand how this dichotomy might be exploited for
therapeutic gain.
Intriguingly, studies implicate a major requirement for oxidative stress in ER stress-induced cell death. Either deletion of CHOP
or providing antioxidants prevented cell death when challenged
with protein misfolding in the ER (Back et al., 2009; Han et al.,
2015; Malhotra and Kaufman, 2007; Malhotra et al., 2008; Song
et al., 2008). Surprisingly, antioxidant treatment also improved
protein folding in the ER, indicating an intimate connection between protein misfolding and oxidative stress (Malhotra et al.,
2008). More recent studies indicate that protein misfolding in the
ER decreases activity of complex I of the respiratory complex,
leading to oxidative stress.
4.5. Autophagy in ischemic preconditioning
Autophagy is an important protective mechanism that is induced by ischemic preconditioning (Carloni et al., 2008; Sheng and
Qin, 2015). Preconditioning treatment reduced cell damage induced by oxygen and glucose deprivation (OGD) in cultured cortical neurons, whereas inhibition of autophagy by 3-MA or baﬁlomycin A1, increased caspase-12, caspase-3 and CHOP protein
levels and suppressed the neuroprotection induced by preconditioning (Sheng et al., 2012). Importantly, inhibition of ER
stress by salubrinal restored neuroprotection mediated by preconditioning in the presence of 3-MA. Moreover, preconditioning
with ER stressors prior to transient MCAO in mice and OGD in
neurons has been shown to afford neuroprotection through eIF2/
ATF4-dependent Parkin-mediated induction of mitophagy (Zhang
et al., 2014). Thus, in the context of ischemia-reperfusion, there is a
hormetic proteostatic mechanism that connects ER stress and
autophagy whereby ER stress-induced apoptosis is inhibited. It
seems that the eIF2/ATF4 pathway plays a pivotal role in ischemic
preconditioning; on one hand by compensating for autophagy
overload through global translational suppression, and on the
other by promoting clearance of damaged mitochondria though
mitophagy. In addition, inhibition of ER stress by autophagy was
observed after neonatal hypoxia/ischemia (Carloni et al., 2014).
Overall autophagy is an important proteostatic response that
protects neurons after preconditioning, and this protective effect
can be modulated by manipulating the UPR. These studies highlight the elegant coordination of multiple proteostatic mechanisms in neuronal preconditioning and that upregulation of a
proximal defense strategy (autophagy) can reduce the need for a
downstream rescue (the UPR). The cyclical crosstalk and contextdependent redundancy between these pathways means that proteostatic disturbances can be effectively ‘triaged’ under conditions
of metabolic compromise in the healthy cell. This provides a network of targets that might be adjusted with synergetic beneﬁt in
both acute and chronic neuronal injury.
4.6. UPS in ischemia
It is thought that the UPS (Box 2) has an important role during
ischemia. Indeed, several in vivo studies have reported that
ischemia depletes free ubiquitin and leads to the accumulation of
ubiquitinated proteins that tend to form aggregates in neurons (Hu
et al., 2000, 2001). For example, in a global ischemia model induced by a transient two-vessel occlusion in rats, neurons in the
hippocampal CA1 region showed accumulation of ubiquitin-conjugates in aggregate-like clusters (Hu et al., 2000). These clusters
were preferentially found in dying neurons suggesting that proteasomal dysfunction could be the cause of neuron death (Yamashiro et al., 2007). It seems therefore that ischemia is associated
with a perturbation of proteostasis; an accumulation of Ub-proteins into aggregates that may interfere with optimal UPS function.

The impairment of proteasomal function by pathological protein
aggregates was also observed in neurodegenerative diseases
(Ciechanover and Kwon, 2015). For example, in prion disease the
infectious form of the prion protein (PrP-Sc) with its exposed beta
sheet composition, interacts and interferes with the gate opening
of the proteasome, limiting the entry of substrates (Andre and
Tabrizi, 2012). This is reminiscent of AD, in which ubiquitinated
and oligomeric tau protein interacts with and inhibits the recognition site of the 19S proteasome subunit (Tai et al., 2012). In
addition, the proteolytic core of the proteasome can become
blocked by hyperphoshorylated tau leading to ERAD impairment
and thereafter UPR activation (Keck et al., 2003; Abisambra et al.,
2013). Whether this represents an adaptive or maladaptive response remains controversial. Indeed, since mild UPR activation
can precondition human neurons, rapid tau hyperphosphorylation
under hypothermic conditions has been proposed as a trigger for
UPR-mediated proteostatic priming in response to cooling (Rzechorzek et al., 2015, 2016).
Whether the formation of aggregates containing ubiquitinated
proteins or simply monomeric and oligomeric misfolded proteins
induce toxicity during ischemia is unclear and is hotly debated in
neurodegenerative disease. It was proposed that protein aggregates trap translational components, chaperones and protein
folding enzymes and thus contribute to proteostatic disruption in
brain ischemia (DeGracia and Montie, 2004; Liu et al., 2005).
However, a more recent study showed that reperfusion rather than
ischemia leads to the formation of aggregates after transient
MCAO. This might be due to massive oxidation of proteins caused
by the burst of reactive oxygen species (ROS) (Grune et al., 2004)
and echoes the adverse effects of the re-warming phase after
therapeutic cooling for brain ischemia (Choi et al., 2012; Rzechorzek et al., 2016). Furthermore, permanent ischemia did not
lead to aggregate formation despite maximally impairing the
proteasome (Hochrainer et al., 2012). This study rather proposes
an alternative mechanism in which the impairment of the proteasome is due to the selective processing of the 26S proteasome
subunit Rpn10 by calpain (Huang et al., 2013). Thus, aggregates of
ubiquitinated proteins may not be the relevant mechanism for
proteasome impairment and neuronal death. This is further supported by an elegant study with live imaging tracking of neurons
expressing Huntingtin-polyQ proteins showing that aggregates
(inclusion bodies) are preferentially observed in surviving neurons
– i.e. neurons that do not accumulate aggregates tend to die more
rapidly (Arrasate et al., 2004). These results indicate that aggregates are protective and may function as a sink by trapping
toxic monomeric or oligomeric Htt-polyQ proteins (Arrasate and
Finkbeiner, 2012). Thus, impairment of proteasome function in HD
and also in brain ischemia may be due to the accumulation of
relatively soluble toxic monomers and oligomers, rather than insoluble protein aggregates. Conceptually, we can consider the
following scenario during the course of disease: in the early phase,
small amounts of modiﬁed/misfolded protein and UPS impairment
would promote UPR and ERAD – and potentially hormesis if the
insult is mild. Long-term, or if the insult is too acute or severe,
CHOP-mediated apoptosis or regulated necrosis is expected.
4.7. UPS in ischemic tolerance
The UPS has an important role in the adaptive response to
ischemia. First, it was shown that activation of the UPS during
ischemic tolerance induces the ubiquitination and degradation of
pro-apoptotic factors. This is the case for Bim which is ubiquitinated and targeted to proteasome-mediated degradation through
preconditioning induced by transient OGD (30 min). This resulted
in the protection of cultured cortical neurons submitted to a more
prolonged OGD (120 min) (Meller et al., 2006). Proteasome-
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dependent degradation of Bim and neuroprotection was also observed by preconditioning of adenosine A1 receptors with adenosine in cultured rat cortical neurons (Ordonez et al., 2010). This
led to an increased resistance to apoptosis – a phenomenon also
observed with the upregulation of Bcl-2 proteins by H2O2-mediated oxidative preconditioning (Calabrese, 2016b). In addition, it
was shown that during rapid ischemic preconditioning the UPS
protects neurons from excitotoxicity via post-synaptic remodeling
(Meller et al., 2008). This is consistent with an immediate and
active role of the UPS in ischemic tolerance.
An important perspective for logistically-feasible application of
neuroprotective conditioning in the clinic is that treatment may
also be of value after the injury has occurred (postconditioning).
Indeed, conditioning has exhibited a protective effect even if administered a few hours after trauma (Stetler et al., 2014). For example, it was shown that ischemic postconditioning cycles reduced the size of cerebral infarction induced by MCAO in adult
rats. The postconditioning treatment improved brain integrity,
which was associated with an increased activity of the proteasome
and anti-oxidant (SOD, catalase) enzymes with a subsequent reduction of oxidized proteins and aggregates (Li et al., 2012).
Postconditioning-induced neuroprotection was also associated
with restoration of proteasome function in neurons of the hippocampal CA1 region in rats subjected to the transient two-vesselocclusion model of global ischemia (Liang et al., 2012). These
studies and others indicate that a functional UPS is essential for
ischemic tolerance and that proteasome inhibition can lead to
neuronal death. This hypothesis is supported by the results
showing that IU1, an inhibitor of Usp14 (a deubiquitinase that acts
as a negative regulator of the proteasome), reduces the infarct
volume resulting from transient MCAO in mice. The effects of IU1
were correlated with regulation of REST, a protein whose expression is increased in neurons destined to die in brain ischemia
(Doeppner et al., 2013). In these studies IU1 was administered
before the ischemic injury and, therefore, future studies should
characterize the effect of proteasome activation after the lesion
has been induced.
Despite the results above showing a role for proteasome inhibition in neuronal demise in brain ischemia, it is interesting to
note that proteasome inhibitors have induced neuroprotection in
several models of stroke. This apparent contradiction may be explained by the effect of proteasome inhibitors on the suppression
of the immunoproteasome and inﬂammation that occurs after
stroke. Indeed, proteasome inhibitors such as MLN519 reduce inﬂammation by downregulating NF-κB and downstream inﬂammatory genes and by decreasing the recruitment of inﬂammatory cells into the brain (Berti et al., 2003; Phillips et al.,
2000; Williams et al., 2003, 2004, 2005; Zhang et al. 2001). Another proteasome inhibitor, BSc2118, protected from stroke in mice
subjected to intraluminal MCAO, by stabilizing the blood–brain
barrier and upregulating HIF1-α (Doeppner et al., 2012). A more
recent study by the same group showed that a single intraperitoneal injection of BSc2118 induced a sustained brain recovery by acting on the peripheral immune response and inhibiting the immunosuppression that is associated with stroke
(Doeppner et al., 2015).
4.8. tPA in ischemic tolerance
tPA is not only a drug injected in the acute phase of cerebral
ischemia to restore the blood ﬂow. It is also a serine protease
synthetized and released by neurons with many, and sometimes
opposite, effects in the brain (Chevilley et al., 2015). Due to its
proteolytic activity, tPA cleaves many cerebral substrates which
induce important cell fate or adaptive mechanisms. During development and axon growth, tPA activates plasminogen into
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Box 2–the ubiquitin proteasome system
The first barrier of defense against the accumulation of
misfolded proteins is the ubiquitin (Ub)-proteasome system
(UPS) (Ciechanover, 2015). In this selective proteolytic
system, Ub is first activated by Ub-activating enzyme E1
and transferred to Ub-conjugating enzyme E2. The Ub is then
transferred to a protein substrate via a specific Ub ligase E3,
which varies depending on its substrate. Several Ubs are
successively added to the protein leading to a chain of four or
more Ub. Ub-conjugated proteins are delivered to the 26S
proteasome, a cylindrical structure that is composed of a
catalytic 20S subunit and one or two 19S regulatory particles
(Clague and Urbe, 2010; Finley, 2009). Proteins are deubiquitinated, unfolded and cleaved into small peptides by
peptidylglutamyl-like (cleaving after acidic residues), trypsin-like (cleaving after basic residues) and chymotrypsin-like
(cleaving after hydrophobic residues) activities, while going
through the proteasome machinery (Tanahashi et al., 2000).
Dysfunction of the UPS due to mutations in the ubiquitinase/
deubiquitinase and proteasome machineries help us to
understand the importance of the UPS to proteostasis.
Indeed, UPS dysfunction is a common hallmark of protein
misfolding disorders including neurodegenerative diseases
such as AD, HD, PD, ALS, prion diseases and ischemia
(Morimoto, 2008; Rubinsztein, 2006; Caldeira et al., 2014;
Ciechanover and Kwon, 2015; Dennissen et al., 2012)

plasmin to degrade the extracellular matrix (Garcia-Rocha et al.,
1994). Many other tPA substrates have been identiﬁed, including
the GluN1 subunit of NMDA receptors (Nicole et al., 2001). tPA also
has a wide range of other functions including activation of
ADAMTS-4 to promote neuroplasticity (Lemarchant et al., 2014),
conversion of pro-BDNF into BDNF to promote LTP in the hippocampus (Pang et al., 2004), and activation of PDGF-C (Fredriksson
et al., 2004) to promote cell proliferation.

5. Adaptation in glioblastoma
Cancer cells often activate adaptive responses to cope with
oncogenic and environmental stresses. As such, cancer cells have
not only to deal with an accelerated metabolism that can be
caused by oncogene overexpression (i.e. MYC) but also with a
challenging microenvironment (i.e. nutrient starvation or hypoxia). High-grade glioma (also known as glioblastoma multiforme,
GBM) is the most frequent and aggressive brain cancer, which still
lacks effective therapeutics. It is associated with a strong UPRmediated adaptive response (Pierre-Jean Le Reste et al., see associated manuscript of this series). GBM is notoriously resistant to
treatment and recurrence leads to a poor clinical outcome (Louis
et al., 2007; Pyrko et al., 2007). The UPR has become a therapeutic
target of interest in cancer and one potential strategy is to either
genetically or pharmacologically invalidate UPR components to
reduce cancer cell resistance to their environment and to increase
their sensitivity to treatment (Hetz et al., 2013; Mollereau, 2013).
This has been illustrated with BiP/GRP78, which is frequently
overexpressed in cancer including GBM (Martin et al., 2013;
Prabhu et al., 2012; Pyrko et al., 2007). In addition to BiP, the three
branches of the UPR have also been involved in the control of GBM
characteristics. Indeed IRE1, which is the ﬁfth most commonly
mutated kinase in human cancer, contributes to the development
of GBM in experimental models (Auf et al., 2010; Chevet et al.,
2015; Dejeans et al., 2012; Drogat et al., 2007; Jabouille et al., 2015;
Pluquet et al., 2013). More precisely, IRE1 signaling pathways were
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shown to impact on GBM tumor angiogenesis through the regulation of proangiogenic and proinﬂammatory chemokines (Auf
et al., 2010; Pluquet et al., 2013). Moreover, regulated IRE1 dependent decay of mRNA (RIDD) activity was shown to signiﬁcantly
contribute to GBM inﬁltration through the degradation of SPARC
mRNA (Dejeans et al., 2012). In a recent study, mutants for both
the IRE1 kinase and endoribonuclease were used to determine the
speciﬁc contribution of each activity. It was shown that while the
RNAse activity of IRE1 is dispensable for neovascularization, the
inhibition of RNAse resulted in increased glioma motility (Jabouille
et al., 2015). Finally, IRE1 activates the epidermal growth factor
receptor (EGFR) pathway, often found deregulated in GBM, by
upregulating its ligand epirgulin. This is independent of IRE1 kinase activity and of XBP1, but instead requires JNK activation by
IRE1 (Auf et al., 2013). Finally, in human GBM samples high levels
of XBP1 splicing correlated with a poorer prognosis (Pluquet et al.,
2013). These data collectively point toward the seminal role of
IRE1 in the development and progression of GBM. More recently
the PERK and ATF6 arms of the UPR were also shown to be involved in the control of GBM development. Indeed, the PERK
pathway was implicated in the regulation of GBM cell metabolism
(Hou et al., 2015) and response to treatment (Hamed et al., 2010;
Yacoub et al., 2010), whereas the ATF6 pathway was recently reported to contribute to GBM resistance to radiotherapy (Dadey
et al., 2015). Interestingly, a high resolution CRISPR screen also
indicated the contribution of the ATF6 arm of the UPR to GBM
development (Hart et al., 2015). In summary, these results demonstrate the essential role of UPR signaling pathways in GBM
biology, and indicate their potential therapeutic relevance.

6. Conclusions
Cellular adaptation to stress involves the activation of multiple
protective pathways that contribute to restore proteostasis. In neurodegenerative diseases such as PD, adaptive mechanisms that include the UPR, the UPS, autophagy and the anti-oxidant responses
allow neurons to cope with the accumulation of misfolded proteins
for decades. In recent years, researchers have identiﬁed the molecular factors and compounds that regulate these adaptive responses.
In particular, pre- or postconditioning strategies that elicit a mild
insult and promote adaptive UPR responses seem particularly promising to treat acute brain injury such as ischemia. These approaches
have also generated interesting results in animal models of PD
which, in contrast to brain ischemia, progresses slowly over the
lifetime of the individual (Mollereau, 2015). UPR preconditioning
may thus be relevant to human patients with neurodegenerative
disease. Unexpectedly, epidemiologic studies revealed that smokers
have a lower incidence of PD than non-smokers (Ritz et al., 2007).
Almost pure nicotine, which can be delivered from patches or e-cigarettes, can prime the UPR at a low level, hence favoring its adaptive
protective response (rather than its maladaptive outputs) (Srinivasan
et al., 2016). The results from a large clinical trial, testing the neuroprotective effects of a transdermal nicotine patch in early PD, are
awaited (https://clinicaltrials.gov/show/NCT01560754). Convergence
of research efforts to illuminate the proteostatic pathways dictating
cell fate will accelerate the discovery of ‘pleiotropic targets’ – targets
that can be manipulated to impede cellular survival mechanisms
where they are unwanted (i.e. tumor growth) and promote these
mechanisms where they are failing (neurodegeneration).
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